| 1 |
Jacobs JJ, Mont MA, Bozic KJ, et al. American academy of orthopaedic surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty [J]. J Bone Joint Surg Am, 2012, 94(8): 746-747.
|
| 2 |
Harris WH, Salzman EW, Athanasoulis CA, et al. Aspirin prophylaxis of venous thromboembolism after total hip replacement [J]. N Engl J Med, 1977, 297(23): 1246-1249.
|
| 3 |
Harris WH, Athanasoulis CA, Waltman AC, et al. Prophylaxis of deep-vein thrombosis after total hip replacement. Dextran and external pneumatic compression compared with 1.2 or 0.3 gram of aspirin daily [J]. J Bone Joint Surg Am, 1985, 67(1): 57-62.
|
| 4 |
Bala A, Huddleston JI, Goodman SB, et al. Venous thromboembolism prophylaxis after TKA: aspirin, warfarin, enoxaparin, or factor Xa inhibitors? [J]. Clin Orthop Relat Res, 2017, 475(9): 2205-2213.
|
| 5 |
Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [J]. Chest, 2004, 126(3 Suppl): 338S-400S.
|
| 6 |
Callaghan JJ, Dorr LD, Engh GA, et al. Prophylaxis for thromboembolic disease - Recommendations from the American College of Chest Physicians - Are they appropriate for orthopaedic surgery? [J]. J Arthroplasty, 2005, 20(3): 273-274.
|
| 7 |
Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J]. Chest, 2012, 141(2 Suppl): e278S-e325S.
|
| 8 |
Jameson SS, Baker PN, Deehan DJ, et al. Evidence-base for aspirin as venous thromboembolic prophylaxis following joint replacement [J]. Bone Joint Res, 2014, 3(5): 146-149.
|
| 9 |
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration [J]. PLoS Med, 2009, 6(7): e1000100.
|
| 10 |
OCEBM Levels of Evidence Working Group. The 2011 Oxford Centre for Evidenced-Based Medicine (OCEBM) Levels of Evidence.
URL
|
| 11 |
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of InterventionsVersion 5. 1.0. [updated March 2011]. The Cochrane Collaboration, 2011,
URL
|
| 12 |
Sterne JAC, Higgins JPT, Reeves BC, on behalf of the development group for ACROBAT-NRSI. A Cochrane Risk Of Bias Assessment Tool: for Non-RandomizedStudies of Interventions (ACROBAT-NSRI), Version 1.0.0, 2014,
URL
|
| 13 |
Anderson DR, Dunbar MJ, Bohm ER, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial [J]. Ann Intern Med, 2013, 158(11): 800-806.
|
| 14 |
Gelfer Y, Tavor H, Oron A, et al. Deep vein thrombosis prevention in joint arthroplasties - Continuous enhanced circulation therapy vs low molecular weight heparin [J]. J Arthroplasty, 2006, 21(2): 206-214.
|
| 15 |
Kulshrestha V, Kumar S. DVT prophylaxis after TKA: routine anticoagulation vs risk screening approach - a randomized study [J]. J Arthroplasty, 2013, 28(10): 1868-1873.
|
| 16 |
Gill SK, Theodorides A, Smith N, et al. Wound problems following hip arthroplasty before and after the introduction of a direct thrombin inhibitor for thromboprophylaxis [J]. Hip Int, 2011, 21(6): 678-683.
|
| 17 |
Beksaç B, González Della Valle A, Anderson J, et al. Symptomatic thromboembolism after one-stage bilateral THA with a multimodal prophylaxis protocol [J]. Clin Orthop Relat Res, 2007, 463: 114-119.
|
| 18 |
Westrich GH, Bottner F, Windsor RE, et al. VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty [J]. J Arthroplasty, 2006, 21(6 Suppl 2): 139-143.
|
| 19 |
Zou Y, Tian S, Wang Y, et al. Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty [J]. Blood Coagul Fibrinolysis, 2014, 25(7): 660-664.
|
| 20 |
Sehat KR, Evans R, Newman JH. How much blood is really lost in total knee arthroplasty? - Correct blood loss management should take hidden loss into account [J]. Knee, 2000, 7(3): 151-155.
|
| 21 |
Jiang Y, Du H, Liu J, et al. Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial [J]. Chin Med J (Engl), 2014, 127(12): 2201-2205.
|
| 22 |
Intermountain Joint Replacement Center Writing Committee. A prospective comparison of warfarin to aspirin for thromboprophylaxis in total hip and total knee arthroplasty [J]. J Arthroplasty, 2012, 27(1): 1-9.e2.
|
| 23 |
Cafri G, Paxton EW, Chen Y, et al. Comparative effectiveness and safety of drug prophylaxis for prevention of venous thromboembolism after total knee arthroplasty [J]. J Arthroplasty, 2017, 32(11): 3524-3528.e1.
|
| 24 |
Bloch BV, Patel V, Best AJ. Thromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacement [J]. Bone Joint J, 2014, 96B(1): 122-126.
|
| 25 |
Hamilton SC, Whang WW, Anderson BJ, et al. Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study [J]. J Arthroplasty, 2012, 27(9): 1594-1598.
|
| 26 |
Gillette BP, Desimone LJ, Trousdale RT, et al. Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty [J]. Clin Orthop Relat Res, 2013, 471(1): 150-154.
|
| 27 |
Chen MS, Lincoff AM. Direct thrombin inhibitors [J]. Curr Cardiol Rep, 2005, 7(4): 255-259.
|
| 28 |
Jameson SS, Charman SC, Gregg PJ, et al. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement a non-randomised comparison from information in the national joint registry [J]. J Bone Joint Surg Br, 2011, 93B(11): 1465-1470.
|
| 29 |
Jameson SS, Baker PN, Charman SC, et al. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after knee replacement: a non-randomised comparison using National Joint Registry Data [J]. J Bone Joint Surg Br, 2012, 94(7): 914-918.
|
| 30 |
Khatod M, Inacio MC, Bini SA, et al. Pulmonary embolism prophylaxis in more than 30,000 total knee arthroplasty patients: is there a best choice? [J]. J Arthroplasty, 2012, 27(2): 167-172.
|
| 31 |
Bozic KJ, Vail TP, Pekow PS, et al. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? [J]. J Arthroplasty, 2010, 25(7): 1053-1060.
|
| 32 |
Poultsides LA, Gonzalez Della Valle A, Memtsoudis SG, et al. Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens [J]. J Bone Joint Surg Br, 2012, 94(1): 113-121.
|
| 33 |
Cusick LA, Beverland DE. The incidence of fatal pulmonary embolism after primary hip and knee replacement in a consecutive series of 4253 patients [J]. J Bone Joint Surg Br, 2009, 91(5): 645-648.
|
| 34 |
Howie C, Hughes H, Watts AC. Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study [J]. J Bone Joint Surg Br, 2005, 87(12): 1675-1680.
|
| 35 |
Pedersen AB, Mehnert F, Sorensen HT, et al. The risk of venous thromboembolism, myocardial infarction, stroke, major bleeding and death in patients undergoing total hip and knee replacement: a 15-year retrospective cohort study of routine clinical practice [J]. Bone Joint J, 2014, 96-B(4): 479-485.
|
| 36 |
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [J]. BMJ, 2002, 324(7329): 71-86.
|
| 37 |
Lussana F, Squizzato A, Permunian ET, et al. A systematic review on the effect of aspirin in the prevention of post-operative arterial thrombosis in patients undergoing total hip and total knee arthroplasty [J]. Thromb Res, 2014, 134(3): 599-603.
|
| 38 |
Parvizi J, Jacovides CL, Bican O, et al. Is deep vein thrombosis a good proxy for pulmonary embolus? [J]. J Arthroplasty, 2010, 25(6 Suppl): 138-144.
|
| 39 |
Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials [J]. Lancet, 2001, 358(9275): 9-15.
|
| 40 |
Della Valle CJ, Steiger DJ, Dicesare PE. Duplex ultrasonography in patients suspected of postoperative pulmonary embolism following total joint arthroplasty [J]. Am J Orthop (Belle Mead NJ), 2003, 32(8): 386-388.
|
| 41 |
Cordoba G, Schwartz L, Woloshin S, et al. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review [J]. Br Med J, 2010, 341: 3920.
|
| 42 |
Patel VP, Walsh M, Sehgal B, et al. Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty [J]. Journal of Bone and Joint Surgery-American Volume, 2007, 89A(1): 33-38.
|
| 43 |
Jaberi MF, Eslampour A, Haytmanek CT, et al. Persistent surgical wound drainage after total hip and knee arthroplasty-risk factors and final outcome [J]. J Bone Joint Surg Br, 2009, 91-B(Suppl II): 298.
|
| 44 |
Carrothers AD, Rodriguez-Elizalde SR, Rogers BA, et al. Patient-reported compliance with thromboprophylaxis using an oral factor Xa inhibitor (rivaroxaban) following total hip and total knee arthroplasty [J]. J Arthroplasty, 2014, 29(7): 1463-1467.
|
| 45 |
Rogers BA, Phillips S, Foote J, et al. Is there adequate provision of venous thromboembolism prophylaxis following hip arthroplasty? An audit and international survey [J]. Ann R Coll Surg Engl, 2010, 92(8): 668-672.
|
| 46 |
Schousboe JT, Brown GA. Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty [J]. J Bone Joint Surg Am, 2013, 95(14): 1256-1264.
|
| 47 |
Parvizi J, Huang R, Restrepo C, et al. Low-Dose aspirin is effective chemoprophylaxis against clinically important venous thromboembolism following total joint arthroplasty: a preliminary analysis [J]. J Bone Joint Surg Am, 2017, 99(2): 91-98.
|
| 48 |
Deirmengian GK, Heller S, Smith EB, et al. Aspirin can be used as prophylaxis for prevention of venous thromboembolism after revision hip and knee arthroplasty [J]. J Arthroplasty, 2016, 31(10): 2237-2240.
|
| 49 |
Ogonda L, Hill J, Doran E, et al. Aspirin for thromboprophylaxis after primary lower limb arthroplasty: early thromboembolic events and 90 day mortality in 11,459 patients [J]. Bone Joint J, 2016, 98-B(3): 341-348.
|